Le Lézard
Classified in: Health
Subject: LEG

FDAnews Announces -- FDA 483s, Warning Letters & Enforcement Trends Webinar, Nov. 25, 2019


FALLS CHURCH, Va., Nov. 13, 2019 /PRNewswire-PRWeb/ -- FDA 483s, Warning Letters & Enforcement Trends
An FDAnews Webinar
Monday, Nov. 25, 2019, 1:30 p.m. ? 3:00 p.m. EST
https://www.fdanews.com/483swarningletters

What's the chance of getting hit with a 483 or warning letter in 2020? And what can one do to avoid it?

Get an early warning on problem areas to focus on. Mark the calendar for Monday, Nov. 25.

Former FDA assistant counsel John Fuson Esq. of Crowell & Moring LLP and his colleague Chalana Damron Esq. take attendees on a deep dive inside FDA enforcement thinking. Attendees will discover what the agency is pinpointing and what it's soft-pedaling:

Strengthen quality and compliance systems!

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

Webinar Details:
FDA 483s, Warning Letters & Enforcement Trends
An FDAnews Webinar
Monday, Nov. 25, 2019, 1:30 p.m. ? 3:00 p.m. EST
https://www.fdanews.com/483swarningletters

Tuition:
$287 per site

Easy Ways to Register:
Online: https://www.fdanews.com/483swarningletters
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations

 

SOURCE FDAnews


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: